Wedbush Issues Positive Forecast for Oruka Therapeutics (NASDAQ:ORKA) Stock Price

Oruka Therapeutics (NASDAQ:ORKA) had its target price increased by Wedbush from $45.00 to $85.00 in a report published on Wednesday morning, MarketBeat.com reports. Wedbush currently has an outperform rating on the stock.

A number of other brokerages have also recently commented on ORKA. Guggenheim restated a “buy” rating and set a $125.00 price target on shares of Oruka Therapeutics in a research note on Monday. Stifel Nicolaus raised their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Piper Sandler started coverage on shares of Oruka Therapeutics in a research note on Thursday, December 18th. They set an “overweight” rating and a $75.00 price target for the company. BTIG Research raised their price target on shares of Oruka Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 16th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $78.90.

Oruka Therapeutics Stock Down 2.3%

Shares of ORKA opened at $65.55 on Wednesday. The stock has a market cap of $3.25 billion, a price-to-earnings ratio of -35.24 and a beta of -0.54. Oruka Therapeutics has a 12 month low of $8.31 and a 12 month high of $67.94. The company has a 50-day moving average price of $41.37 and a two-hundred day moving average price of $33.23.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.16. Equities research analysts expect that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the transaction, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. The trade was a 18.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total transaction of $71,407.70. Following the completion of the transaction, the chief executive officer owned 927,309 shares of the company’s stock, valued at $38,297,861.70. This trade represents a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 23,765 shares of company stock valued at $1,089,745 in the last quarter. 24.69% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Fairmount Funds Management LLC raised its stake in shares of Oruka Therapeutics by 9.9% in the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after acquiring an additional 333,340 shares during the last quarter. Viking Global Investors LP bought a new position in shares of Oruka Therapeutics in the third quarter valued at approximately $51,280,000. Deep Track Capital LP raised its stake in shares of Oruka Therapeutics by 38.4% in the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after acquiring an additional 735,983 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Oruka Therapeutics by 38.1% in the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after purchasing an additional 676,865 shares in the last quarter. Finally, RTW Investments LP increased its holdings in shares of Oruka Therapeutics by 5.8% in the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after purchasing an additional 112,499 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

Key Stories Impacting Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $85 and assigned an “outperform” rating, a notable bullish signal that increases upside expectations for ORKA. Wedbush raises ORKA target
• Positive Sentiment: BTIG boosted its price target to $78, adding further analyst-driven momentum that may support buying interest. BTIG raises ORKA target to $78
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $70 target while publishing multi‑quarter and FY2026–FY2027 EPS forecasts (FY2027: -$3.55), signaling continued analyst conviction despite losses; this sustained buy-side research supports the stock’s rally. HC Wainwright coverage
• Neutral Sentiment: An insider (Joana Goncalves) sold 7,000 shares under a pre‑arranged Rule 10b5‑1 plan, reducing her stake ~17.3%; because the sale was pre‑planned and disclosed via SEC Form 4, it’s less likely to signal new negative information, but it can still be perceived as supply pressure. SEC Form 4
• Negative Sentiment: Consensus and firm forecasts confirm continued multi‑year losses (consensus FY current year ~ -$3.41 EPS; HC Wainwright FY2027 -$3.55), which keeps valuation reliant on future clinical/ commercial successes and may cap multiple expansion despite high price‑target activity.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.